Y-27632 (Dihydrochloride)RHO/ROCK pathway inhibitor; Inhibits ROCK1 and ROCK2, 10 mg

StemCell Technologies Inc has been awarded contract A207_PO-0411179-V3 by the University of Virginia on June 13, 2026. The contract pertains to the delivery of Y-27632 (Dihydrochloride), a Rho/ROCK pathway inhibitor that selectively inhibits ROCK1 and ROCK2 kinases. The specified unit quantity is 10 mg per delivery unit. The contract is administered within the Commonwealth of Virginia; however, specific contract value, cumulative value, annual value, and performance period information are not provided in the available documentation.

The line item specification indicates a unit price structure with deliveries directed to the University of Virginia as the buyer. While the contract documentation does not specify a particular county location or detailed performance schedule, the contracting organization's status as a major research institution suggests the delivered product will support scientific or medical research applications. Additional contractual details, including total contract value, performance period duration, and specific delivery locations beyond the University of Virginia, are not available from the provided award information.